Pacira BioSciences (PCRX) Total Non-Current Liabilities (2010 - 2026)

Pacira BioSciences' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $538.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 30.07% year-over-year to $538.9 million; the TTM figure through Mar 2026 stood at $538.9 million (down 30.07% YoY), while the FY2025 annual figure was $551.2 million, down 27.31% from the prior year.
• Total Non-Current Liabilities was $538.9 million for Q1 2026 at Pacira BioSciences, down from $551.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.1 billion in Q1 2022 to a low of $538.9 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $755.1 million across 5 years, with a median of $745.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities soared 80.24% in 2022, then plunged 33.91% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $878.1 million in 2022, then dropped by 21.34% to $690.7 million in 2023, then advanced by 9.8% to $758.4 million in 2024, then decreased by 27.31% to $551.2 million in 2025, then decreased by 2.25% to $538.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $538.9 million (Q1 2026), $551.2 million (Q4 2025), and $552.5 million (Q3 2025), per Business Quant data.